BRIEF—HiberCell launches with $60 million in series A funding

Backed by $60 million in series A financing, a new biotech firm called HiberCell has launched in New York. The company will focuses on tumor dormancy detection and therapeutics. The funding round was led by ARCH Venture Partners.

The firm will look to develop first-in-class therapeutics targeting dormant disseminated tumor cells (DTCs) originating from solid and liquid cancers.

Co-founder and chief scientific officer Alan Rigby said: "HiberCell is the foundational tumor dormancy company. We know that dormant disseminated tumor cells are critical drivers of cancer metastasis.”

“We believe that this approach provides a differentiated opportunity to change the paradigm of cancer treatment," he added.